Cadila Pharmaceuticals Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is RALOXIFENE HYDROCHLORIDE USP, with a corresponding US DMF Number 27064.
Remarkably, this DMF maintains an Active status since its submission on May 06, 2013, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 15, 2014, and payment made on September 11, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II